Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study.

被引：3
|
作者：
Yu, Evan Y.
Massard, Christophe
Retz, Margitta
Tafreshi, Ali
Carles, Joan
Hammerer, Peter
Fong, Peter C. C.
Shore, Neal D.
Joshua, Anthony M.
Linch, Mark David
Gurney, Howard
Romano, Emanuela
Augustin, Marinela
Piulats, Josep M.
Wu, Helen
Schloss, Charles
Poehlein, Christian Heinrich
De Bono, Johann S.
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Gustave Roussy Canc Campus, Villejuif, France
[3] Univ Paris Sud, Villejuif, France
[4] Tech Univ Munich, Rechts Isar Univ Hosp, Munich, Germany
[5] Univ Wollongong, Wollongong, NSW, Australia
[6] Vall dHebron Univ Hosp, Barcelona, Spain
[7] Acad Hosp Braunschweig, Braunschweig, Germany
[8] Auckland City Hosp, Auckland, New Zealand
[9] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[10] St Vincents Hosp, Kinghorn Canc Ctr, Sydney, NSW, Australia
[11] UCL, Inst Canc, London, England
[12] Macquarie Univ Hosp, Sydney, NSW, Australia
[13] Inst Curie, Paris, France
[14] Klinikum Nurnberg, Nurnberg, Germany
[15] Catalan Canc Inst, Barcelona, Spain
[16] Merck & Co Inc, Kenilworth, NJ USA
[17] Royal Marsden Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.5027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5027
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
    Yu, Evan Y.
    Massard, Christophe
    Retz, Margitta
    Tafreshi, Ali
    Carles Galceran, Joan
    Hammerer, Peter
    Fong, Peter C. C.
    Shore, Neal D.
    Joshua, Anthony
    Linch, Mark David
    Gurney, Howard
    Romano, Emanuela
    Augustin, Marinela
    Piulats, Josep M.
    Wu, Haiyan
    Schloss, Charles
    Poehlein, Christian Heinrich
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [2] Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A update
    Arranz Arija, J. A.
    Yu, E. Y.
    Piulats, J. M.
    Gravis, G.
    Laguerre, B.
    Oudard, S.
    Fong, P. C.
    Kolinsky, M. P.
    Augustin, M.
    Todenhofer, T.
    Kam, A. E.
    Gurney, H.
    Tafreshi, A.
    Retz, M.
    Berry, W. R.
    Mar, N.
    Wu, H.
    Qiu, P.
    Schloss, C.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S513 - S514
  • [3] KEYNOTE-365 Cohort A: Pembrolizumab Plus Olaparib in Docetaxel-Pretreated Patients With Metastatic Castrate-Resistant Prostate Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 14 - 15
  • [4] KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Yu, Evan Y.
    Piulats, Josep M.
    Gravis, Gwenaelle
    Laguerre, Brigitte
    Arija, Jose Angel Arranz
    Oudard, Stephane
    Fong, Peter C. C.
    Kolinsky, Michael Paul
    Augustin, Marinela
    Feyerabend, Susan
    Kam, Audrey E.
    Gurney, Howard
    Tafreshi, Ali
    Retz, Margitta
    Berry, William R.
    Mar, Nataliya
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [5] Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.
    Massard, Christophe
    Retz, Margitta
    Hammerer, Peter
    Quevedo, Fernando
    Fong, Peter C. C.
    Berry, William R.
    Gurney, Howard
    Piulats, Josep M.
    Joshua, Anthony M.
    Linch, Mark David
    Kolinsky, Michael Paul
    Romano, Emanuela
    Sridhar, Srikala S.
    Conter, Henry Jacob
    Augustin, Marinela
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.
    Fong, Peter C. C.
    Retz, Margitta
    Drakaki, Alexandra
    Massard, Christophe
    Berry, William R.
    Romano, Emanuela
    De Bono, Johann S.
    Feyerabend, Susan
    Appleman, Leonard Joseph
    Conter, Henry Jacob
    Sridhar, Srikala S.
    Shore, Neal D.
    Linch, Mark David
    Joshua, Anthony M.
    Gurney, Howard
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.
    Yu, Evan Y.
    Piulats Rodriguez, Jose Maria M.
    Gravis, Gwenaelle
    Laguerre, Brigitte
    Arranz Arija, Jose Angel
    Oudard, Stephane
    Fong, Peter C. C.
    Kolinsky, Michael Paul
    Augustin, Marinela
    Todenhofer, Tilman
    Kam, Audrey E.
    Gurney, Howard
    Tafreshi, Ali
    Retz, Margitta
    Berry, William R.
    Mar, Nataliya
    Wu, Haiyan
    Qiu, Ping
    Schloss, Charles
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Pembrolizumab (pembro) plus lenvatinib (lenva) in patients (pts) with docetaxel-pretreated, metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort E.
    Augustin, Marinela
    Laguerre, Brigitte
    Baldini, Capucine
    Zedan, Ahmed H.
    Gonzalez-Billalabeitia, Enrique
    Fong, Peter C. C.
    Zukov, Ruslan
    Hammerer, Peter
    Prentice, Mark
    Shore, Neal D.
    Necchi, Andrea
    Todenhoefer, Tilman
    Kessler, Elizabeth R.
    Kose, Fatih
    Gurney, Howard
    Valderrama, Begona Perez
    Zhu, Pengfei
    Imai, Kentaro
    Liu, Yingjie
    McDermott, Raymond S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 148 - 148
  • [9] Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
    Massard, Christophe
    Retz, Margitta
    Hammerer, Peter
    Quevedo, Fernando
    Fong, Peter C. C.
    Berry, William R.
    Gurney, Howard
    Piulats, Josep M.
    Joshua, Anthony
    Linch, Mark David
    Kolinsky, Michael
    Romano, Emanuela
    Sridhar, Srikala S.
    Conter, Henry Jacob
    Augustin, Marinela
    Wu, Haiyan
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [10] Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
    Fong, Peter C. C.
    Retz, Margitta
    Drakaki, Alexandra
    Massard, Christophe
    Berry, William R.
    Romano, Emanuela
    De Bono, Johann S.
    Feyerabend, Susan
    Appleman, Leonard Joseph
    Conter, Henry Jacob
    Sridhar, Srikala S.
    Shore, Neal D.
    Linch, Mark David
    Joshua, Anthony
    Gurney, Howard
    Wu, Haiyan
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
12345